Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
MeVis Medical Solutions AG is a German software company specializing in medical imaging solutions. It develops, markets, and sells advanced software for recording, analyzing, and evaluating image data from modalities such as computed tomography, mammography, magnetic resonance imaging, and digital sonography. The company's products target manufacturers of medical devices, providers of medical IT platforms, and clinical end-users primarily in the United States and Europe, with a clinical emphasis on early detection and diagnosis of key diseases including breast, lung, liver, and neurological conditions. Founded in 1997 and headquartered in Bremen, Germany, MeVis Medical Solutions AG originated from research at Bremen University and the German Cancer Research Center. It separated from the Fraunhofer Institute for Medical Image Computing MEVIS to focus on commercial products, listing on the stock exchange in 2007. As a subsidiary of Varex Imaging Corporation, it employs over 140 staff and offers complementary services like software development outsourcing, three-dimensional visualizations, interactive online training for clinicians, and teleradiology applications. MeVis plays a vital role in enhancing image-based diagnostics and therapy, bridging scientific innovation with practical medical benefits.
14.58% operating margin is respectable but not wide. ROIC at 12.68%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 5.4% YoY. Margins deteriorated 9.0pp alongside, both lines moving the wrong way.
ROIC dropped from 21.85% to 12.68%, capital efficiency is deteriorating. Operating margin contracted 9.0pp YoY, cost discipline may be slipping.
Profitability & Returns
Revenue (TTM)
€16M
▼ -5.4% YoY
Net Income (TTM)
€3M
▼ -30.6% YoY
Op. Margin
14.58%
▼ -9.0pp YoY
ROIC
12.68%
▼ -9.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€4M
▲ +31.4% YoY
Op. Cash Flow (TTM)
€4M
▼ -8.2% YoY
Net Debt
-€7M
Net Cash Position
Cash & Equiv.
€7M
3Y CAGR: -5.0%
3Y CAGR: -7.5%
Continue Research